Gilead Sciences announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH).
Pfizer says that its investigational, next-generation tyrosine kinase inhibitor lorlatinib showed clinically meaningful activity against lung tumors and brain metastases in a phase 2 trial in patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC).
miRagen Therapeutics has announced new interim results from its ongoing phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).
The Infectious Disease Research Institute (IDRI) and American Leprosy Missions have started a Phase 1 clinical trial in humans for leprosy vaccine candidate, the first vaccine developed specifically for leprosy.
Ardelyx has released positive results from its second Phase 3 study of tenapanor, dubbed T3MPO-2, for irritable bowel syndrome with constipation (IBS-C).
Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.
The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.
A DNA-based Zika vaccine, dubbed GLS-5700, developed by a consortium led by Inovio Pharmaceuticals and GeneOne Life Science succeeded in a phase 1 clinical trial by producing anti-Zika response in humans.
UK-based Motif Bio reported that its skin disorder drug iclaprim has succeeded in a second phase 3 trial in patients with acute bacterial skin and skin structure infections (ABSSSI).
NHS patients are taking part in a world-first trial for a universal flu vaccine supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.